Daisuke Suzuki
Tokai University
72 Papers
220 Citations
Daisuke Suzuki is an academic researcher from Tokai University. The author has contributed to research in topics: Medicine & Febrile neutropenia. The author has an hindex of 13, co-authored 62 publications.
Chat about Author
Papers
•Journal Article
Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy.
Tomoya Umezono,Masao Toyoda,Mayuko Kato,Masaaki Miyauchi,Moritugu Kimura,Mayumi Maruyama,Masashi Honma,Mitsunori Yagame,Daisuke Suzuki +8 more
TL;DR: The study indicated that CTGF and TGF-beta may play an important role in glomerular histopathologic change in DN.
48
Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study
Hirozumi Sano,Ryoji Kobayashi,Daisuke Suzuki,Kenji Kishimoto,Kazue Yasuda,Kunihiko Kobayashi +5 more
TL;DR: Both PIPC/TAZ and CFPM were effective and safe as an empirical therapy for FN in children and no serious adverse effects occurred in either of groups.
21
Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases.
Hirozumi Sano,Ryoji Kobayashi,Akihiro Iguchi,Daisuke Suzuki,Kenji Kishimoto,Kazue Yasuda,Kunihiko Kobayashi +6 more
TL;DR: It was found that a history of relapse, a refractory state of underlying disease, and high C-reactive protein concentrations at the beginning of fever were significant risk factors for mortality after developing sepsis.
20
Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
Mizuho Ichikawa,Daisuke Suzuki,Junjiro Ohshima,Yuko Cho,Makoto Kaneda,Akihiro Iguchi,Tadashi Ariga +6 more
TL;DR: The aim of this study was to evaluate the efficacy and safety of piperacillin/tazobactam (PIP/TAZO) and cefozopran (CZOP) monotherapy in pediatric cancer patients with febrile neutropenia.
19
A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders
TL;DR: This randomized prospective study was designed to assess whether piperacillin/tazobactam (PIPC/TAZ) is as effective as meropenem (MEPM) as a first‐line antibiotic treatment for febrile neutropenia (FN).
17